Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 12, 2026 06:25 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® delivered substantial weight loss in women across all menopause stages, plus heart and migraine protection, shown in new Novo Nordisk data at the European Congress on Obesity

Novo Nordisk today announced data demonstrating that Wegovy® delivers substantial and consistent weight-loss results for women.
May 12, 2026 02:00 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Higher dose Wegovy® demonstrates nearly 28% weight loss in early responders according to new analyses presented at the European Congress on Obesity

Higher-dose Wegovy led to up to 28% weight loss, mainly from fat, with muscle preserved, new trial data show.
May 06, 2026 01:31 ET | Source: Novo Nordisk A/S

Novo Nordisk's adjusted operating profit reached DKK 32,858 million in Q1 2026

The strong performance of Wegovy® and continued growth in International Operations have led us to raise our 2026 guidance for both adjusted sales and ...
April 28, 2026 16:01 ET | Source: PMGC Holdings Inc.

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atrophy, and Certain Neurological Disorders

UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions relate
April 28, 2026 08:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to present new data on Wegovy®, women with obesity and next-generation weight loss treatments at European Congress on Obesity

Novo Nordisk will present new clinical data and real-world evidence at the European Congress on Obesity, 12–15 May in Istanbul, Turkey.
April 09, 2026 08:28 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® injection becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU

Wegovy® injection is the first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
March 27, 2026 16:05 ET | Source: PMGC Holdings Inc.

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in Combination with GLP-1 Treatments

NorthStrive Biosciences Signs Licensing Agreement Amendment with MOA Life Plus [KOSDAQ: 142760] for Dual Myostatin Assets Targeting Muscle Preservation in
March 19, 2026 11:40 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss

US FDA has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term.
February 17, 2026 08:58 ET | Source: Novo Nordisk A/S

Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average

Final EU approval of high-maintenance dose of Wegovy. The new dose gives healthcare professionals even more flexibility to tailor treatment.
February 09, 2026 06:59 ET | Source: Novo Nordisk A/S

Novo Nordisk takes legal action against Hims & Hers to protect patients from unsafe, knock-off Wegovy® and Ozempic®

Novo Nordisk has filed a lawsuit against telehealth firm Hims & Hers for patent infringement and putting patients’ lives at stake with knockoff drugs.